Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of common shares. The offering is priced at $0.795 per common share and $0.005 per warrant, with the warrants carrying an exercise price of $0.84 per share. Aggregate gross proceeds are expected to be approximately $2.9 million, before deducting placement agent fees and other offering expenses.
The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, together with its existing cash, cash equivalents, restricted cash and investment-grade securities, for working capital and general corporate purposes. This capital infusion is pivotal for the company as it continues to develop and commercialize its scalable, non-animal protein production platforms, which address growing global demand across life sciences, food and nutrition, and bio-industrial markets.
Dyadic's proprietary Dapibus™ and C1 expression systems are designed to enable rapid, cost-effective and flexible manufacturing of high-value proteins, allowing customers to create more efficient, scalable and sustainable products. The funding will support the company's ongoing efforts to bring these innovative technologies to market, potentially transforming how proteins are produced for various industries.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. The company has filed a registration statement with the Securities and Exchange Commission (SEC) for the shares offered in the registered direct offering, and the offering is being made only by means of a prospectus. The private placement warrants are being issued in a concurrent private placement, which is not registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
The announcement of this capital raise is significant for Dyadic as it provides the financial resources needed to advance its pipeline and expand its commercial reach. With the global demand for sustainable and animal-free proteins on the rise, Dyadic is well-positioned to capitalize on this trend. The company's focus on scalable protein production platforms aligns with the increasing interest in alternative proteins that are both efficient and environmentally friendly.
For more information on the offerings, visit the full press release at https://ibn.fm/od7FJ. To learn more about Dyadic International and its technologies, visit https://dyadic.com/.
